Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccinein HIV-1 infected persons
GAO Jin-jin1, HUANG Jian-wen2, LEI Qian2, HE Jian-mei3, ZHENG Jun3, ZOU Xiao-bai3, CHEN Xi1,3
1. School of Public Health, Nanhua University, Hengyang, Hunan 421001, China; 2. Lanshan County Center for Disease Control and Prevention, Lanshan, Hunan 425800, China; 3. Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan 410008, China
Abstract：Objective To observe the effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine (PPV23) in HIV-1 infected persons, to evaluate safety, protective effect and cost-effectiveness of the vaccination, and to provide a basis for formulating the relevant policies. Methods We surveyed 145 HIV-1 infected persons vaccinated with PPV23 in Lanshan county in 2017-2019 by a self-designed questionnaire and telephone or face-to-face interview, and collected their incidence of pneumonia-related diseases, adverse reactions after vaccination, and information about and cost of diagnosis and therapy of related diseases before and after vaccination with PPV23 within one year. Results Among the 145 HIV-1 infected persons vaccinated with PPV23, the incidence rates of respiratory tract diseases and pneumonia after vaccination were lower than those before vaccination (P<0.05), but no change was found in CD4+ T-lymphocyte cell count. Conclusions PPV23 vaccination in the HIV-1 infected persons is conducive to reducing the incidence of opportunistic pulmonary infection,and has a good safety and cost-effectiveness. It is worthy of being promoted in the HIV-infected persons.
[1] Raju R, Peters BS,Breen RA. Lung infections in the HIV infected adult[J]. Curr Opin Pulm Med, 2012,18(3):253-258. [2] Yin Z, Rice BD, Waight P, et al. Invasive pneumococcal disease among HIV-positive individuals, 2000-2009[J]. AIDS, 2012,26(1):87-94. [3] CDC. Prevention of pneumococcal disease: recommendations of the advisory committee on immunization practices (ACIP)[J].MMWR,1997,46(RR-8). [4] 井良义,从波泉.多价肺炎球菌疫苗的免疫效果及其安全性[J].中国计划免疫,1999,5(4):245-247. [5] 邹力.13价肺炎链球菌结合疫苗和23价肺炎链球菌多糖疫苗在免疫损害人群中的应用:美国免疫实施咨询委员会的建议[J].国际生物制品学杂志,2014.37(3):152-155. [6] 吴尊友.我国实现艾滋病防治策略三个90%的进展与挑战[J].中华疾病控制杂志,2016,20(12):1187-1189. [7] 徐鹏,朱坤,冀洪波,等.艾滋病高流行地区病人住院费用分析[J].中国卫生经济,2009,28(6):33-35. [8] Breiman RF, Keller DW, Phelan MA, et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients[J]. Arch Intern Med, 2000, 160(17):2633-2638. [9] Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV infected individuals[J].Hum Vaccin Immunother,2012,8(2):161-173. [10] French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected Ugandan adults: double-blind, randomized and placebo controlled trial[J]. Lancet, 2000,355(9221):2106-2111. [11] Watera C, Nakiyingi J, Miiro G, et al.23-valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort[J]. AIDS, 2004,18(8):1210-1213. [12] World Health Organization. Essential prevention and care interventions for adults and adolescents living with HIV in resource-limited settings[EB/OL]accessed 25 may zolo. http://www.who.int/hiv/pub/prev_care/OMS_EPP_AFF_en.pdf. [13] Kaplan JE, Benson C,Holmes KK,et al. Guidelines for prevention and treatment of opportunistic infections in HIV infected adults and adolescents: recommendations from CDC, the National Institutes of Health,and the HIV Medicine Association of the Infectious Diseases Society of America [J]. MMWR Recomm Rep,2009,58 (RR-4):1-207. [14] Geretti AM, Brook G, Cameron C, et al. British HIV Association Guidelines on the use of vaccines in HIV positive adults 2015[J].HIV Med, 2016,17(Suppl 3):s2-s81. [15] 金明会,白红,何惠,等.国产23价肺炎球菌多糖疫苗上市后安全性评价[J].职业卫生与病伤,2011,26(5):270-272. [16] 上海市卫生局.关于组织开展60岁以上老年人接种肺炎疫苗工作的通知沪卫计委疾妇〔2013〕004号[EB/OL].(2013-04-26)[2019-01-09].http://www.wsjsw.gov.cn/jbfk2/20180815/58559.html. [17] 北京市卫生健康委员会.北京又一项惠民工程上线啦[EB/OL].(2018-12-16)[2019-01-09]. http://wjw.beijing.gov.cn/xwzx/jcdt/201812/t20181226_260872. htm. [18] 黄建文, 雷倩, 贺健梅,等. 70例成年艾滋病病毒感染者接种肺炎和流感疫苗随访1年效果观察[J]. 中国病毒病杂志, 2017, 7(3):207-209. [19] 阿迪拉·苏力旦,热依拜·亚地佧尔,地力夏提·亚克甫. 新疆伊宁市2006—2015年HIV/AIDS患者生存状况分析[J].实用预防医学,2017,24(2):181-184. [20] 黎雅娟,刘保湘,黄道平,等. 常德市性传播艾滋病病毒感染者/艾滋病患者生存状况及影响因素分析[J]. 实用预防医学, 2018,25(7):837-840. [21] 张军.加强我国疫苗安全性监测与经济学评价研究-正当其时[J].中华预防医学杂志,2019,53(7):661-663.
2020, Vol. 27 
